Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Artigo
|
![]() |
M‐EA (methotrexate, etoposide, dactinomycin) and EMA‐CO (methotrexate, etoposide, dactinomycin / cyclophosphamide, vincristine) regimens as first‐line treatment of high‐risk gestational trophoblastic neoplasiaSingh, Kam ; Gillett, Sarah ; Ireson, Jane ; Hills, Anne ; Tidy, John A. ; Coleman, Robert E. ; Hancock, Barry W. ; Winter, Matthew C.International journal of cancer, 2021-05, Vol.148 (9), p.2335-2344 [Periódico revisado por pares]Hoboken, USA: John Wiley & Sons, IncTexto completo disponível |
2 |
Material Type: Artigo
|
![]() |
First‐Line Durvalumab in Addition to Etoposide and Platinum for Extensive‐Stage Small Cell Lung Cancer: A U.S.‐Based Cost‐Effectiveness AnalysisLin, Shen ; Luo, Shaohong ; Gu, Dian ; Li, Meiyue ; Rao, Xin ; Wang, Changlian ; Huang, Pinfang ; Xu, Xiongwei ; Weng, XiuhuaThe oncologist (Dayton, Ohio), 2021-11, Vol.26 (11), p.e2013-e2020 [Periódico revisado por pares]Hoboken, USA: John Wiley & Sons, IncTexto completo disponível |
3 |
Material Type: Artigo
|
![]() |
Requirement for etoposide in the initial treatment of Epstein‐Barr virus–associated haemophagocytic lymphohistiocytosisSong, Yue ; Wang, Yini ; Wang, ZhaoBritish journal of haematology, 2019-09, Vol.186 (5), p.717-723 [Periódico revisado por pares]England: Blackwell Publishing LtdTexto completo disponível |
4 |
Material Type: Artigo
|
![]() |
Intensified conditioning regimens with total marrow irradiation/etoposide/cyclophosphamide and busulfan/etoposide/cyclophosphamide overcome the impact of pre‐transplant minimal residual disease on outcomes in high‐risk acute lymphoblastic leukemia patients in complete remissionZhao, Xiaoyan ; Xu, Ziwei ; Li, Ziying ; Zhou, Xi ; Hu, Yu ; Wang, HuafangCancer medicine (Malden, MA), 2024-01, Vol.13 (1), p.n/a [Periódico revisado por pares]United States: John Wiley & Sons, IncTexto completo disponível |
5 |
Material Type: Artigo
|
![]() |
Anti‐Metastatic and Anti‐Angiogenic Activities of Core–Shell SiO2@LDH Loaded with Etoposide in Non‐Small Cell Lung CancerZhu, Yanjing ; Zhu, Rongrong ; Wang, Mei ; Wu, Bin ; He, Xiaolie ; Qian, Yechang ; Wang, ShilongAdvanced science, 2016-11, Vol.3 (11), p.1600229-n/a [Periódico revisado por pares]Hoboken: John Wiley and Sons IncTexto completo disponível |
6 |
Material Type: Artigo
|
![]() |
Phase II trial of a novel chemotherapy regimen CVEP (cyclophosphamide, vinblastine, etoposide and prednisolone) for acquired immunodeficiency syndrome (AIDS)-associated lymphomasSengar, Manju ; Jain, Hasmukh ; Shet, Tanuja ; Sridhar, Epari ; Gota, Vikram ; Rangarajan, Venkatesh ; Laskar, Siddhartha S ; Alahari, Aruna ; Thorat, Jayashree ; Agarwal, Archi ; Sharma, Neha ; Gupta, Himanshi ; Kannan, Sadhana ; Kumar, Shikhar ; Nayak, Lingaraj ; Menon, Hari ; Gujral, Sumeet ; Bagal, BhausahebBritish journal of haematology, 2023-02, Vol.200 (4), p.429-439 [Periódico revisado por pares]England: Blackwell Publishing LtdTexto completo disponível |
7 |
Material Type: Artigo
|
![]() |
Results with Floxuridine, Actinomycin D, Etoposide, and Vincristine in Gestational Trophoblastic Neoplasias with International Federation of Gynecology and Obstetrics Scores ≥5Li, Yuan ; Kong, Yujia ; Wan, Xirun ; Feng, Fengzhi ; Ren, Tong ; Zhao, Jun ; Yang, Junjun ; Xiang, YangThe oncologist (Dayton, Ohio), 2021-12, Vol.26 (12), p.e2209-e2216 [Periódico revisado por pares]Hoboken, USA: John Wiley & Sons, IncTexto completo disponível |
8 |
Material Type: Artigo
|
![]() |
Etoposide and cisplatin versus irinotecan and cisplatin as the first‐line therapy for patients with advanced, poorly differentiated gastroenteropancreatic neuroendocrine carcinoma: A randomized phase 2 studyZhang, Panpan ; Li, Jie ; Li, Jian ; Zhang, Xiaotian ; Zhou, Jun ; Wang, Xicheng ; Peng, Zhi ; Shen, Lin ; Lu, MingCancer, 2020-05, Vol.126 (S9), p.2086-2092 [Periódico revisado por pares]United States: Wiley Subscription Services, IncTexto completo disponível |
9 |
Material Type: Artigo
|
![]() |
Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first‐relapse/primary refractory diffuse large B‐cell lymphomaFeldman, Tatyana ; Mato, Anthony R. ; Chow, Kar F. ; Protomastro, Ewelina A. ; Yannotti, Kara M. L. ; Bhattacharyya, Pritish ; Yang, Xiao ; Donato, Michele L. ; Rowley, Scott D. ; Carini, Carolanne ; Valentinetti, Marisa ; Smith, Judith ; Gadaleta, Gabriella ; Bejot, Coleen ; Stives, Susan ; Timberg, Mary ; Kdiry, Sabrina ; Pecora, Andrew L. ; Beaven, Anne W. ; Goy, AndreBritish journal of haematology, 2014-07, Vol.166 (1), p.77-83 [Periódico revisado por pares]Oxford: BlackwellTexto completo disponível |
10 |
Material Type: Artigo
|
![]() |
Ruxolitinib‐combined doxorubicin‐etoposide‐methylprednisolone regimen as a salvage therapy for refractory/relapsed haemophagocytic lymphohistiocytosis: a single‐arm, multicentre, phase 2 trialWang, Jingshi ; Zhang, Rui ; Wu, Xiaoyan ; Li, Fei ; Yang, Haixia ; Liu, Ligen ; Guo, Haixia ; Zhang, Xuejun ; Mai, Huirong ; Li, Hui ; Wang, ZhaoBritish journal of haematology, 2021-05, Vol.193 (4), p.761-768 [Periódico revisado por pares]England: Blackwell Publishing LtdTexto completo disponível |